SOA partners with US companies for drug development collaboration

Share this story

Prof (Dr) Manojranjan Nayak and Dr Mukund S Chorghade.

Bhubaneswar: Siksha ‘O’ Anusandhan Deemed to be University (SOA) is set to embark on a collaborative research venture with US-based THINQ Pharma and Ayurvidya Healthcare Innovations. The focus of this collaboration is the development of pharmaceuticals derived from both natural and synthetic sources to combat challenging diseases.

The decision was made during a meeting held on Saturday, where SOA founder president Prof (Dr) Manojranjan Nayak engaged in discussions with Dr Mukund S Chorghade, a distinguished scientist serving as the president and chief scientific officer of THINQ Pharma and Ayurvidya Healthcare Innovations. The collaboration aims to bring together researchers from various disciplines such as pharmacy, biotechnology, medical sciences, and engineering.

Also read: SOA joins hands with India Millet Initiative and Sorghum United

Dr Chorghade, an esteemed Fellow of the American Chemical Society (ACS), is renowned for his expertise in Drug Discovery and Development, Process Chemistry Derived Medicinal Chemistry, and Traditional Indian Medicine. His past achievements include the discovery of ‘chemosynthetic artificial livers,’ catalysts with applications in drug metabolism, biomass valorization, and environmental remediation.

The collaborative effort will involve a team of scientists from the US company and SOA, led by Prof Kulamani Parida, director of SOA’s Centre for Nano Sciences and Nano Technology. Notable attendees at the meeting included Prof Lala Bihari Sukla, Prof Hruday Nath Thattoi, Prof Gyana Ranjan Rout, Prof Sanghamitra Nayak, Prof E Subudhi, Prof Pratap Kumar Sahoo, Prof BB Subudhi, and Prof Laxmidhar Maharana from various departments.

This strategic partnership aims to contribute to the development of novel drugs and drug products, fostering advancements in the field of pharmaceuticals.

Share this story